Skip to main content
Advertisement
Advertisement

TOVX

TOVX logo

Theriva Biologics, Inc.

0.23
USD
Sponsored
0.00
-1.79%
Sep 24, 15:53 UTC -4
Closed
exchange

Pre-Market

0.24

+0.01
+2.82%

TOVX Earnings Reports

Positive Surprise Ratio

TOVX beat 35 of 42 last estimates.

83%

Next Report

Date of Next Report
Nov 10, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/
-$0.06
Implied change from Q2 26 (Revenue/ EPS)
--
/
-14.29%
Implied change from Q3 25 (Revenue/ EPS)
--
/
-86.67%

Theriva Biologics, Inc. earnings per share and revenue

On Aug 11, 2026, TOVX reported earnings of -0.07 USD per share (EPS) for Q2 26, missing the estimate of -0.05 USD, resulting in a -37.25% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -0.43% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 4 analysts forecast an EPS of -0.06 USD, with revenue projected to reach -- USD, implying an decrease of -14.29% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
PharmaCyte Biotech, Inc. Common Stock
Report Date
Sep 14, 2026 For Q1 27
Estimate
-
Actual
-$0.54
Surprise
-
FAQ
For Q2 2026, Theriva Biologics, Inc. reported EPS of -$0.07, missing estimates by -37.25%, and revenue of $0.00, 0% as expectations.
The stock price moved down -0.43%, changed from $0.23 before the earnings release to $0.23 the day after.
The next earning report is scheduled for Nov 10, 2026.
Based on 4 analysts, Theriva Biologics, Inc. is expected to report EPS of -$0.06 and revenue of -- for Q3 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement